Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and dea...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Circulation
Asıl Yazarlar: Kosiborod, Mikhail, Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Holl, Reinhard W., Norhammar, Anna, Birkeland, Kåre I., Jørgensen, Marit Eika, Thuresson, Marcus, Arya, Niki, Bodegård, Johan, Hammar, Niklas, Fenici, Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2017
Konular:
Original Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5515629/
https://ncbi.nlm.nih.gov/pubmed/28522450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller